Vijay Aluri
Rheumatology · Cedar Rapids, IANPI 1215979539
Payments from drug & device makers
What this record shows
3 manufacturers reported payments, led by Amgen at 49.3% of the total.
Across 10 payments — averaging $38.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$191
- Johnson & Johnson$167
- AbbVie$29
What the payments were for
- Food & beverage$17345%
- Education$21455%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 5 | $191 |
| Johnson & Johnson | 3 | $167 |
| AbbVie | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$118
How this compares
$387 in reported general payments places this provider in the 65th percentile of 50 rheumatology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 127 | $926,666 |
| Enbrel SureclickEtanercept | 22 | $204,968 |
| Actemra ActpenTocilizumab | 23 | $112,932 |
| Humira(Cf)Adalimumab | 12 | $76,260 |
| OrenciaAbatacept | 11 | $69,339 |
| Hydroxychloroquine Sulfate | 676 | $23,809 |
| MethotrexateMethotrexate Sodium | 475 | $12,378 |
| Leflunomide | 139 | $6,976 |
| Sulfasalazine DrSulfasalazine | 40 | $2,075 |
| Sulfasalazine | 53 | $1,919 |
| Mycophenolate Mofetil | 13 | $1,827 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 89 | $1,531 |
| Colchicine | 49 | $1,522 |
| Leucovorin Calcium | 31 | $1,223 |
| Alendronate Sodium | 244 | $869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $29 | $76,26012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 50 rheumatology providers in Iowa.
Other rheumatology in Cedar Rapids
- Adnan KianiCedar Rapids$2K
- Michael BrooksCedar Rapids$414
- Harinder SinghCedar Rapids$387
- Bogdan CherascuCedar Rapids$186
- Paul RothmanIowa City$217K
- Hanna ZembrzuskaIowa City$30K
- George IsaacDubuque$5K
- Christopher RonkarUrbandale$5K
- Sunita PenmatchaBettendorf$4K
- Mudappa KalaiahBettendorf$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.